Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 2/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | CEL | P19835 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11023325 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL11021457 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL11019093 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| Bromide SCHEMBL19330051 | 0.97 | CYP1A2 (0.54) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL3691804 | 0.97 | — | — | |
| SCHEMBL11154618 | 0.92 | SIGMAR1 (0.56) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL79050 | 0.92 | SIGMAR1 (0.56) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL19922821 | 0.92 | — | — | |
| SCHEMBL12375433 | 0.91 | CYP1A2 (0.48) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL7619522 | 0.90 | SIGMAR1 (0.60) | CYP1A2SIGMAR1EPHX1KDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617756-B2 | Substituted imidazolidines for treating a RNA virus infection | ABIVAX (FR) | 2026-05-05 | — | — | US | disclosed |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| EP-3966199-B1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2026-03-18 | — | — | EP | disclosed |
| US-12528773-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2026-01-20 | — | — | US | disclosed |
| EP-4647432-A1 | AROMATIC COMPOUND, ORGANIC SEMICONDUCTOR LAYER, AND ORGANIC THIN FILM TRANSISTOR | Tosoh Corporation (JP) | 2025-11-12 | — | — | EP | disclosed |
| CN-112703183-B | Aryl-N-aryl derivatives for the treatment of RNA viral infections | ABIVAX公司 | 2025-06-10 | — | — | CN | disclosed |
| US-12247018-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | ABIVAX (FR) | 2025-03-11 | — | — | US | disclosed |
| CN-114174263-B | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2024162378-A1 | AROMATIC COMPOUND, ORGANIC SEMICONDUCTOR LAYER, AND ORGANIC THIN FILM TRANSISTOR | 東ソー株式会社 | 2024-08-08 | — | — | WO | disclosed |
| CN-110770214-B | Heterocyclic P2X7 antagonists | 布雷耶疗法有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-1998005327-A1 | SUBSTITUTED AROMATIC COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997048697-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1997-12-24 | — | — | WO | disclosed |
| EP-0447188-B1 | 7-Oxabicycloheptane imidazole prostaglandin analogs useful in the treatment of thrombotic and vasospastic diseases | SQUIBB & SONS INC (US) | 1995-06-28 | — | — | EP | disclosed |
| EP-0447188-A2 | 7-Oxabicycloheptane imidazole prostaglandin analogs useful in the treatment of thrombotic and vasospastic diseases | E.R. SQUIBB & SONS, INC. (US) | 1991-09-18 | — | — | EP | disclosed |
| EP-0403090-A1 | 7-oxabicycloheptane imidazole prostaglandin analogs useful in the treatment of thrombotic and vasopastic disease | E.R. SQUIBB & SONS, INC. (US) | 1990-12-19 | — | — | EP | disclosed |
| US-4977174-A | Anticoagulants, antischemic agents | E. R. SQUIBB & SONS, INC. (US) | 1990-12-11 | — | — | US | disclosed |
| EP-0046961-B1 | EPOXY-CYCLOALKYLALKANECARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICAMENTS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1985-02-13 | — | — | EP | disclosed |
| US-4430339-A | PROPHYLAXIS, METABOLISM, GLUCOSE, FATS, HYPOGLYCEMIC AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-02-07 | — | — | US | disclosed |
| WO-1982000822-A1 | SUBSTITUTED OXIRANECARBOXYLIC ACIDS,THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | EISTETTER K | 1982-03-18 | — | — | WO | disclosed |
| EP-0046961-A1 | Epoxy-cycloalkylalkanecarboxylic acids, process for their preparation, their use and medicaments containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1982-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528773-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, GAA | CYP1A2 2573/4885SIGMAR1 745/4885EPHX1 1134/4885 |
| US-12617756-B2 | Substituted imidazolidines for treating a RNA virus infection | NSUN2, NSUN3, ZC3HAV1 | CYP1A2 2047/4885SIGMAR1 304/4885EPHX1 3988/4885 |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | CYP1A2 2435/4885SIGMAR1 1034/4885EPHX1 1284/4885 |
| US-12247018-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | CRKL, VRK2, FRK | CYP1A2 1897/4885SIGMAR1 577/4885EPHX1 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.